Factor V Leiden (FVL) is the most common genetic risk factor for venous thromboembolism (VTE) and occurs in about 5% of the Caucasian population. It is considered to be a moderate risk factor for VTE, and its clinical expression is influenced by co-existing genetic factors, in addition to acquired and circumstantial risk factors. FVL status seems to have little or no effect on recurrence risk of VTE, does not influence treatment following a VTE event, and is not an indication for primary prophylactic treatment in asymptomatic carriers. There is consensus that in some circumstances genetic testing for FVL has utility, as carriers should be educated about circumstances that might increase the likelihood of VTE, signs and symptoms of VTE, and the potential need for prophylactic anticoagulation in high-risk circumstances.

**WHAT IS FACTOR V LEIDEN?**

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a multifactorial disease resulting from a combination of genetic, environmental and circumstantial risks. DVT is estimated to occur in about 1 per 1000 persons per year and is predominant in older age groups. PE occurs less often. Individuals who have experienced a VTE are at increased risk for a recurrent episode. Factor V is a clotting factor with activity regulated by the anti-coagulant activated protein C (APC). A single base substitution in the factor V gene (G>A at position 1691) results in the elimination of one of APC’s three cleavage sites. This mutation causes factor V to be inactivated more slowly by APC, generating more thrombin and consequently increasing the potential for clot formation. This specific mutation in the factor V gene is called factor V Leiden (FVL).

FVL is the most common genetic risk factor for VTE. Other co-existing inherited and acquired disorders and circumstantial risk factors affect clinical expression of FVL, for example, also carrying the prothrombin variant 2010G>A (carrying both the FVL and 2010G>A alleles occurs in about 1/1000 of the general population), obesity, age, immobility due to injury, surgery or air travel, oral contraceptives, hormone replacement therapy (HRT), selective estrogen receptor modulator (SERMs) or pregnancy. Heart attack, arterial thrombosis and ischemic stroke are not associated with FVL.

This GEC-KO Messenger will focus exclusively on FVL. FVL is inherited in an autosomal dominant manner. About 5% of the Caucasian population carries the FVL mutation with the prevalence being lower in other ethnicities (about 2% in Hispanic Americans and about 1% in African Americans). Homozygosity for FVL (both copies of the FV gene having the mutation) occurs much less often, in about 1 per 5000 Caucasian individuals. About 20-25% of individuals with VTE, 40-50% of individuals with recurrent VTE or estrogen related thrombosis, and about 50% of individuals with familial thrombophilia are found to have FVL.

**RED FLAGS TO CONSIDER GENETIC TESTING OR GENETIC CONSULTATION**

Genetic testing for FVL may have clinical utility in certain circumstances (table 1), however there is no evidence that knowledge of FVL carrier status influences treatment following a VTE event to avoid recurrence. Similarly, there is no evidence that primary prophylactic treatment in asymptomatic carriers improves clinical outcome.
Table 1. Summary of scenarios where genetic testing for FVL may be indicated.¹,⁴

<table>
<thead>
<tr>
<th>Testing is appropriate in the following circumstances:</th>
<th>Other clinical circumstances in which testing may be appropriate include the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑ A first unprovoked VTE at any age (especially age &lt; 50 years)</td>
<td>☑ Female smokers &lt; 50 years with a myocardial infarction or stroke</td>
</tr>
<tr>
<td>☑ A history of recurrent VTE</td>
<td>☑ Women with recurrent unexplained first-trimester pregnancy losses, or an unexplained fetal loss after 10 weeks gestation, or stillbirth</td>
</tr>
<tr>
<td>☑ Venous thrombosis at unusual sites (e.g., cerebral, mesenteric, hepatic, or portal veins)</td>
<td>☑ Selected women with unexplained severe preeclampsia, placental abruption, or a fetus with severe intrauterine growth restriction</td>
</tr>
<tr>
<td>☑ VTE and a strong family history of thrombotic disease</td>
<td>☑ A first VTE related to the use of tamoxifen or other selective estrogen receptor modulators (SERMs)</td>
</tr>
<tr>
<td>☑ VTE during pregnancy or the puerperium</td>
<td>☑ Neonate or child with non-catheter-related idiopathic VTE or stroke</td>
</tr>
<tr>
<td>☑ VTE associated with the use of estrogen contraception or hormone replacement therapy (HRT)</td>
<td>☑ Asymptomatic adult family members of individuals with a known FVL mutation, especially those with a strong family history of VTE at a young age (&lt;50y), when that knowledge may influence pregnancy management, consideration of estrogen contraception use or pregnancy</td>
</tr>
<tr>
<td>☑ A first VTE and a first-degree family member with VTE &lt; 50 years</td>
<td></td>
</tr>
</tbody>
</table>

*Because thrombosis rarely occurs before young adulthood, asymptomatic relatives younger than 18 years are not usually tested, even relatives of homozygotes.*⁴

FVL testing is not routinely recommended:¹,⁴
- For the general population
- During routine pregnancy screening
- Before prescribing estrogen contraception, HRT or SERMs
- For prenatal testing or screening of asymptomatic newborns, neonates, and children
- For patients with a personal or family history of arterial thrombosis (acute coronary syndrome or stroke), unless unexplained in an individual under age 50

**WHAT DOES THE GENETIC TEST RESULT MEAN?**

Population studies suggest that about 10% of FVL carriers develop VTE over their lifetime; the risk is higher for those with a family history of thrombophilia (~25-40%).¹ Carriers of FVL and individuals who are homozygous (carrying the FVL change in both FV genes) have an increased lifetime risk for VTE, but that absolute risk is very small. For example, in the general population women under age 40 have a background risk of VTE of 8/100,000, whereas female FVL carriers of the same age have a VTE risk of 24/100,000 and the homozygote risk for women in that age range is 8/10,000.¹² FVL heterozygosity has, at most, a moderate effect on recurrence risk. FVL homozygosity effect on recurrence risk is not well defined. FVL carriers do not, however, have an increased risk for mortality or morbidity.¹
SURVEILLANCE AND MANAGEMENT

Individuals at high risk for clotting
Those with a history of recurrent VTE, especially at a young age, or those with a strong family history of VTE at a young age should, in addition to FVL testing, be screened for:

- Protein C activity
- Antithrombin activity
- Free Protein S antigen or Protein S activity
- Prothrombin variant 20210G>A

Asymptomatic FVL carriers
Table 2. Management recommendations for asymptomatic FVL carriers.

<table>
<thead>
<tr>
<th>Education</th>
<th>Additional testing</th>
<th>During high risk situations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carriers should be educated about:</td>
<td>FVL is often seen with other inherited and/or acquired disorders.</td>
<td>During high-risk clinical situations (e.g. surgery, pregnancy) prophylactic anticoagulation may prevent some VTE episodes. However, there is no evidence confirming the benefit of primary prophylaxis for asymptomatic FVL heterozygotes.</td>
</tr>
<tr>
<td>✓ Circumstances that might increase the likelihood of VTE (obesity, age, surgery, reduced mobility due to injury or travel, use of oral contraceptives, HRT, or SERMs, and pregnancy)</td>
<td>An individual with FVL should be tested for other thrombophilia disorders to better assess the absolute risk of thrombosis. Consider:</td>
<td>Decisions regarding prophylactic anticoagulation should be based on a risk/benefit assessment in each individual case.</td>
</tr>
<tr>
<td>✓ The signs and symptoms of VTE that require immediate medical attention</td>
<td>Genetic testing for prothrombin 20210G&gt;A variant</td>
<td>Consultation with a specialist may be considered.</td>
</tr>
<tr>
<td>✓ The potential need for prophylactic anticoagulation in high-risk circumstances (e.g. postpartum)</td>
<td>Serologic assays for anticardiolipin antibodies and antithrombin antibodies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multiple phospholipid-dependent coagulation assays for a lupus inhibitor</td>
<td></td>
</tr>
</tbody>
</table>

Following a VTE event
Management of individuals with FVL depends on clinical circumstances. The first acute VTE should be treated according to standard guidelines. In the absence of other indications, FVL carrier status is not an indication for prolonged treatment.

In cases of unprovoked VTE in a FVL carrier, for FVL homozygotes, and for those with multiple thrombophilic disorders (e.g. carriers of both FVL and the prothrombin 20210G>A variant), long-term antithrombotic prophylaxis should be considered; however, the true risk-benefit ratio of extended anticoagulation treatment is not known.

FVL and pregnancy
The Society of Obstetricians and Gynaecologists of Canada (SOGC) recently published guidelines regarding diagnosis, treatment and thromboprophylaxis of VTE in pregnancy and postpartum which are available on the website www.sogc.org under Clinical Practice Guidelines.

References


Other FVL resources:
Thrombosis Canada [http://thrombosiscanada.ca/](http://thrombosiscanada.ca/)

Authors: S Morrison MS CGC, JC Carroll MD CCFP and JE Allanson MD FRCPC

*GEC-KO* Messenger is for educational purposes only and should not be used as a substitute for clinical judgement. *GEC-KO* aims to aid the practicing clinician by providing informed opinions regarding genetic services that have been developed in a rigorous and evidence-based manner. Physicians must use their own clinical judgement in addition to published articles and the information presented herein. *GEC-KO* assumes no responsibility or liability resulting from the use of information contained herein.